Because of great levels of PD-L1 expression, ranging from 23% to 92% for thymomas and from 34% to 88% for TCs, PD-1/PD-L1 inhibitors have been tested in TETs showing a promising clinical activity. The gene discussed is CD274; the disease is thymoma.